Nuklearmedizin 2020; 59(01): 33-34
DOI: 10.1055/a-1044-1855
Case Report
© Georg Thieme Verlag KG Stuttgart · New York

PSMA-negative prostate cancer and the continued value of choline-PET/CT

Ian Alberts
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Christos Sachpekidis
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Viktor Fech
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Axel Rominger
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
,
Ali Afshar-Oromieh
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. November 2019 (online)

Short introduction

Owing to their superior uptake and higher detection rate, PSMA-labelled radioligands have largely replaced choline in routine clinical imaging of recurrent prostate cancer (PCa). Nevertheless, even at high PSA values, a small number of patients can present with PSMA negative prostate cancer (PC) lesions. For such patients choline PET continues to play an important role.